Loading...
Receive $200 for creating an Interactive Brokers account using our link: Create IBKR account. Read our Interactive Brokers analysis
- Ticker
- BBOT
- Price
- 11.25
- Stock movement down
- -0.14 (-1.23%)
- Company name
- BridgeBio Oncology Therapeutics, Inc.
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 890.96M
- Ent value
- 520.31M
- Price/Sales
- -
- Price/Book
- 1.99
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -
- 1 year return (CAGR)
- -
- 3 year return (CAGR)
- -
- 5 year return (CAGR)
- -
- 10 year return (CAGR)
- -
Last updated: 2026-01-22
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
BBOT does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | - |
| Price to Book | 1.99 |
| EV to Sales | - |
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 79.20M |
| EPS (TTM) | -4.89 |
| FCF per share (TTM) | -3.09 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 0.00 |
| Gross profit (TTM) | 0.00 |
| Operating income (TTM) | -124.29M |
| Net income (TTM) | -114.93M |
| EPS (TTM) | -4.89 |
| EPS (1y forward) | -2.05 |
Margins
Loading...
Margins data
| Gross margin (TTM) | - |
| Operating margin (TTM) | - |
| Profit margin (TTM) | - |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 408.74M |
| Net receivables | 226.00K |
| Total current assets | 476.01M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 3.27M |
| Total assets | 484.79M |
| Accounts payable | 3.65M |
| Short/Current long term debt | 2.89M |
| Total current liabilities | 35.71M |
| Total liabilities | 38.09M |
| Shareholder's equity | 446.70M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -94.74M |
| Capital expenditures (TTM) | 936.00K |
| Free cash flow (TTM) | -72.67M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -25.73% |
| Return on Assets | -23.71% |
| Return on Invested Capital | -25.70% |
| Cash Return on Invested Capital | -16.25% |
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 11.43 |
| Daily high | 11.58 |
| Daily low | 11.24 |
| Daily Volume | 164K |
| All-time high | 13.73 |
| 1y analyst estimate | 24.20 |
| Beta | - |
| EPS (TTM) | -4.89 |
| Dividend per share | 0.00 |
| Ex-div date | - |
| Next earnings date | - |
Downside potential
Loading...
Downside potential data
| BBOT | S&P500 | |
| Current price drop from All-time high | -18.06% | -0.89% |
| Highest price drop | -19.37% | -19.00% |
| Date of highest drop | 3 Dec 2025 | 8 Apr 2025 |
| Avg drop from high | -8.02% | -2.49% |
| Avg time to new high | 8 days | 6 days |
| Max time to new high | 45 days | 89 days |
COMPANY DETAILS
Marketcap
890.96M
Marketcap category
Small-cap
Description
BridgeBio Oncology Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of small-molecule therapeutics targeting renin-angiotensin system and phosphoinositide 3-kinase malignancies. The company's product pipeline includes BBO-8520, a direct inhibitor targeting the on and off states of KRAS that is in Phase I clinical trial to treat patients with KRASG12C mutant non-small cell lung cancer; and BBO-10203, an orally bioavailable small molecule that is in Phase I clinical trial for treatment of patients with HER2+ breast cancer, HR+/HER2- breast cancer, KRAS pancreatic ductal adenocarcinoma (PDAC), KRAS mutant colorectal cancer (CRC), and KRAS mutant NSCLC. It is also developing BBO-11818, an orally bioavailable pan KRAS on/off inhibitor that is in Phase I clinical trial to treat patients with KRASG12D and KRASG12V mutant NSCLC, PDAC, and CRC. The company was founded in 2016 is headquartered in South San Francisco, California.
Employees
81
Website
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
No items found
iO Charts is a Seeking Alpha partner